Know Cancer

or
forgot password

Investigation the Risk Factors for the Leakage of Anticancer Drugs to Systemic Circulation in Patients With Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization


N/A
20 Years
80 Years
Not Enrolling
Both
Hepatocellular Carcinoma

Thank you

Trial Information

Investigation the Risk Factors for the Leakage of Anticancer Drugs to Systemic Circulation in Patients With Hepatocellular Carcinoma Treated by Transcatheter Arterial Chemoembolization


Inclusion Criteria:



- Patients with hepatocellular carcinoma caused by hepatitis B or C who will be treated
by TACE

Exclusion Criteria:

- Previously treated by antiviral drugs for hepatitis B or C

Type of Study:

Observational

Study Design:

Time Perspective: Prospective

Outcome Measure:

The blood levels of anticancer drugs (epirubicin, mitomycin C and cisplatin) will be determined within one hour and at the third day after TACE.

Outcome Time Frame:

within one hour and at the third day after TACE

Safety Issue:

Yes

Principal Investigator

z y lin, MD, Ms

Investigator Role:

Principal Investigator

Investigator Affiliation:

Kaohsiung Medical University

Authority:

Taiwan: Institutional Review Board

Study ID:

KMUH-IRB-960297

NCT ID:

NCT00630240

Start Date:

February 2008

Completion Date:

February 2009

Related Keywords:

  • Hepatocellular Carcinoma
  • epirubicin
  • mitomycin C
  • cisplatin
  • Hepatocellular carcinoma
  • Carcinoma
  • Carcinoma, Hepatocellular

Name

Location